Business
Sareum to present at major research congress in...
Sareum to present at major research congress in....
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n\n\n\n\n (AIM: SAR) 25 October 2010\n\n\n SAREUM HOLDINGS PLC\n\n (\"Sareum\" or the \"Company\")\n\n Sareum to Present at Major Research Congress in China\nSareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to\nannounce that Dr Tim Mitchell, CEO, and Dr John Reader, CSO, will present\nSareum's cancer research programmes and SKIL drug discovery platform at the 8th\nInternational Drug Discovery Sciences and Technology (IDDST) Congress in\nBeijing, China.\n\nToday, Dr Mitchell will present Sareum's SKIL platform at the session focussing\non new kinase inhibitors. Tomorrow (Oct 26), Dr Reader will present Sareum's\nChk-1 and VEGFR-3 cancer research programmes at the symposium dedicated to\ncancer drug discovery.\n\nSareum's CEO, Dr Tim Mitchell, commented: \"China is set to become one of the\nmajor forces in bio-science innovation. This is a significant opportunity for us\nto showcase our drug research programmes and the technology behind them at this\nprestigious congress, as well as at the many company meetings that will take\nplace after the event.\n\n Sareum Holdings plc\n\n Tim Mitchell 01223 497 700\n\n\n\n Merchant Securities Limited (Nomad)\n\n Simon Clements/Bidhi Bhoma 020 7628 2200\n\n\n\n Hybridan LLP (Broker)\n\n Claire Noyce 020 7947 4350\n\n\nNotes for editors:\n\nAbout Sareum Holdings plc\nSareum is a drug discovery company, headquartered in Cambridge UK, that is\nfocused on producing targeted small molecule therapeutics to address unmet\nmedical needs, primarily in cancer. Sareum aims to successfully deliver drug\ncandidates for licensing to pharmaceutical and biotechnology companies at the\npre-clinical or early clinical trials stage.\n\nSareum's Chk1 kinase cancer research programme is a joint research collaboration\nwith The Institute of Cancer Research and Cancer Research Technology Limited.\nNovel chemical compounds developed by the collaboration have been shown to\nincrease the effectiveness of current cancer therapeutics in in-vivo cancer\nmodels.\n\nSKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology\nplatform that has so far produced the Company's Aurora, VEGFR-3, FLT3 & TYK2\nkinase cancer and auto-immune disease research programmes. SKIL can also\ngenerate drug research programmes against other kinase targets.\n\nSareum Holdings plc joined the...